Anti-SARS coronavirus agents: a patent review (2008 – present)

Bibliography

• Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66
   PubMed Web of Science ®Google Scholar
• Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94
   PubMed Web of Science ®Google Scholar
• WHO. Coronavirus never before seen in humans is the cause of SARS 2003
   Google Scholar
• Peiris JSM, Lai ST, Poon LLM, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-25
   PubMed Web of Science ®Google Scholar
• Fouchier RAM, Kuiken T, Schutten M, et al. Aetiology - Koch's postulates fulfilled for SARS virus. Nature 2003;423:240-0
   PubMed Web of Science ®Google Scholar
• Barnard DL, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol 2011;6:615-31
   PubMed Web of Science ®Google Scholar
• Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394-9
   PubMed Web of Science ®Google Scholar
• Spaan WJM, Cavanagh D. Coronaviridae, in virus taxonomy, VIIIth Report of the ICTV. Elsevier Academic Press, London; 2004. p. 945-62
   Google Scholar
• Thiel V, Ivanov KA, Putics A, et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Virol 2003;84:2305-15
   Web of Science ®Google Scholar
• Thiel V, Herold J, Schelle B, Siddell SG. Viral replicase gene products suffice for coronavirus discontinuous transcription. J Virol 2001;75:6676-81
   PubMed Web of Science ®Google Scholar
• Narayanan K, Maeda A, Maeda J, Makino S. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol 2000;74:8127-34
   PubMed Web of Science ®Google Scholar
• Opstelten DJ, Raamsman MJ, Wolfs K, et al. Envelope glycoprotein interactions in coronavirus assembly. J Cell Biol 1995;131:339-49
   PubMed Web of Science ®Google Scholar
• Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 2004;101:9804-9
   PubMed Web of Science ®Google Scholar
• Hon CC, Lam TY, Shi ZL, et al. Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J Virol 2008;82:1819-26
   PubMed Web of Science ®Google Scholar
• Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676-9
   PubMed Web of Science ®Google Scholar
• Wang LF, Eaton BT. Bats, civets and the emergence of SARS. Curr Top Microbiol Immunol 2007;315:325-44
   PubMed Web of Science ®Google Scholar
• Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med 2003;349:2431-41
   PubMed Web of Science ®Google Scholar
• Fielding BC. Human coronavirus NL63: a clinically important virus? Future Microbiol 2011;6:153-9
   PubMed Web of Science ®Google Scholar
• Cui LJ, Zhang C, Zhang T, et al. Human coronaviruses HCoV-NL63 and HCoV-HKU1 in hospitalized children with acute respiratory infections in Beijing, China. Adv Viro 2011;2011:129134
   PubMedGoogle Scholar
• Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20
   PubMed Web of Science ®Google Scholar
• de Groot RJ, Baker SC, Baric RS, et al. Middle east respiratory syndromecoronavirus (MERS-CoV); Announcement of the coronavirus study group. J Virol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Available from: http://www.who.int/csr/disease/coronavirus_infections/update_20130425/en/
   Google Scholar
• Available from: http://www.who.int/csr/don/2013_05_14_ncov/en/index.html
   Google Scholar
• Liang PH. Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem 2006;6:361-76
   PubMed Web of Science ®Google Scholar
• Yanh H, Bartlam M, Rao Z. Drug design targeting the main protease, the Achille's heel of coronavirus. Curr Pharm Des 2006;12:4573-90
   PubMed Web of Science ®Google Scholar
• Ramajayam R, Tan KP, Liang PH. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochem Soc Trans 2011;39:1371-5
   PubMed Web of Science ®Google Scholar
• Keum YS, Jeong YJ. Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target. Biochem Pharmacol 2012;84:1351-8
   PubMed Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7:226-36
   PubMed Web of Science ®Google Scholar
• Chou KC, Wei DQ, Du QS, et al. Progress in computational approach to drug development against SARS. Curr Med Chem 2006;13:3263-70
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Chi YH, Hsu JT, et al. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem Biophys Res Commun 2004;318:862-7
   PubMed Web of Science ®Google Scholar
• Yang H, Yang M, Ding Y, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA 2003;100:13190-5
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300:1763-7
   PubMed Web of Science ®Google Scholar
• Hsu MF, Kuo CJ, Chang KT, et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem 2005;280:31257-66
   PubMed Web of Science ®Google Scholar
• Lindner HA, Fotouhi-Ardakani N, Lytvyn V, et al. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 2005;79:15199-208
   PubMed Web of Science ®Google Scholar
• Barretto N, Jukneliene D, Ratia K, et al. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 2005;79:15189-98
   PubMed Web of Science ®Google Scholar
• Lindner HA. Deubiquitination in virus infection. Virology 2007;362:245-56
   PubMed Web of Science ®Google Scholar
• Boissy G, Peretto I, Delansorne R, et al. Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications. CA2632635A1; 2007
   Google Scholar
• Wang HM, Liang PH. Pharmacophores and biological activities of severe acute respiratory syndrome viral protease inhibitors. Expert Opin Ther Patents 2007;17:533-46
   Web of Science ®Google Scholar
• Kuo C-J, Liu H-G, Lo Y-K, et al. Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett 2009;583:549-55
   PubMed Web of Science ®Google Scholar
• Liang PH, Jung KC, Ge LH, et al. Composition for preventing or treating picornavirus and coronavirus induced diseases containing 3,5-diaryl-4,5-dihydro pyrazol derivatives or pharmaceutically acceptable salts thereof as an active ingredient. KR20100066142A; 2010
   Google Scholar
• Melnick JL. Enterovirus: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses in virology. Lippincott-Raven; Philadephia, PA: 1996
   Google Scholar
• Blomberg J, Lycke E, Ahlfors K, et al. Letter: new enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, and mouth disease. Lancet 1974;2:112
   PubMed Web of Science ®Google Scholar
• Sperber SJ, Hayden FG. Chemotherapy of rhinovirus colds. Antimicrob Agents Chemother 1988;32:409-19
   PubMed Web of Science ®Google Scholar
• Lum LC, Wong KT, Lam SK, et al. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet 1998;352:1391
   PubMed Web of Science ®Google Scholar
• Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999;341:929-35
   PubMed Web of Science ®Google Scholar
• Lee CK, Kono K, Haas E, et al. Characterization of an infectious cDNA copy of the genome of a naturally occurring, avirulent coxsackievirus B3 clinical isolate. J Gen Virol 2005;86:197-210
   PubMed Web of Science ®Google Scholar
• Krausslich HG, Wimmer E. Viral proteinases. Annu Rev Biochem 1988;57:701-54
   PubMed Web of Science ®Google Scholar
• Rao Z, Lou Z, Sun Y, et al. Diterpenes diterpenoids natural product inhibitor for main protease of coronaviruses such as SARS and screen method thereof. CN101418334A; 2009
   Google Scholar
• Rao Z, Ma M, Lou Z, et al. Method for separating SARS coronavirus main proteinase inhibitor from traditional Chinese medicine. CN101701245A; 2010
   Google Scholar
• Rao Z, Ma M, Lou Z, Li X. Method for screening SARS corona virus major protease inhibitor from traditional Chinese medicine and screened SARS corona virus major protease inhibitor. CN101921823A; 2010
   Google Scholar
• Lee WS, Rho MC, Park SJ, et al. Composition for prevention or treatment of coronavirus and composotion for inhibiting the activity of 3C-like protease. KR20110068191A; 2011
   Google Scholar
• Adedeji AO, Marchand B, te Velthuis AJW, et al. Mechanism of nucleic acid unwinding by SARS-CoV helicase. PLoS ONE 2012;7
   PubMed Web of Science ®Google Scholar
• Tanner JA, Watt RM, Chai YB, et al. The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5′ to 3′ viral helicases. J Biol Chem 2003;278:39578-82
   PubMed Web of Science ®Google Scholar
• Chung YH, Jeong YJ, Lee CY. Composition for inhibiting SARS coronavirus comprising aryl diketoacid derivatives. KR20100029528A; 2010
   Google Scholar
• Chung YH, Jeong YJ, Lee CY. Pharmaceutical compositions comprising dihydroxychromone derivatives as an active ingredient for treating and preventing diseases caused by coronaviruses. KR20110006083A; 2011
   Google Scholar
• Rudolph AR, Tuthill CW. Treatment or prevention of respiratory viral infections with alpha thymosin peptides. US2010311656A1; 2010
   Google Scholar
• Lee SH, Hong HB, Kim TW, et al. Peptide compounds for detecting or inhibiting SARS coronavirus and application thereof. US2010304363; 2010
   Google Scholar
• Chong PCS, Hsieh SL. Receptor binding polypeptides. US2009022735A1; 2009
   Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-4
   PubMed Web of Science ®Google Scholar
• Penninger JM, Imai Y, Kuba K, et al. Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries. US2008159962A1; 2008
   Google Scholar
• Fukuda N, Ueno T, Fukushima A, Kuroda K. Ribozyme to cleave coronavirus gene. US2010273997A1; 2010
   Google Scholar
• Fukushima A, Fukuda N, Lai Y, et al. Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus. Intervirology 2009;52:92-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu L, Wang S, et al. Small interfering RNA for restraining SARS corona virus M protein gene expression, encoding gene and application thereof. CN101173275; 2008
   Google Scholar
• Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428:561-4
   PubMed Web of Science ®Google Scholar
• Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 2004;101:9804-9
   PubMed Web of Science ®Google Scholar
• Benoit B, Benoit C, Nicolas E, et al. Vaccine. US2010233250A1; 2010
   Google Scholar
• Benoit B, Benoit C, Nicolas E, et al. Vaccine. US2012045469A1; 2012
   Google Scholar
• Masanori M, Tetsuya U, Hiroshi O. Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof. US2011262529A1; 2011
   Google Scholar
• Babcook JS, Prabhakar BS, Coughlin M. Antibodies to SARS coronavirus. WO2008060331A2; 2008
   Google Scholar
• Coughlin M, Lou G, Martinez O, et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 2007;361:93-102
   PubMed Web of Science ®Google Scholar
• van den Brink EN, Ter Meulen J, Cox F, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol 2005;79:1635-44
   PubMed Web of Science ®Google Scholar
• Ter Meulen JH, van den Brink EN, de Kruif CA, et al. Compositions against SARS-coronavirus and uses thereof. CN101102794A; 2008
   Google Scholar
• Jiang S, He Y. Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus. CN101522208; 2009
   Google Scholar
• Yoon CH, Cho JS. SARS vaccine nano-delivery system. KR20100120473A; 2010
   Google Scholar
• Baritussio A. Use of amiodarone and amiodarone analogues as antiviral agents. WO2008044261A1; 2008
   Google Scholar
• Stadler K, Ha HR, Ciminale V, et al. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Am J Respir Cell Mol Biol 2008;39:142-9
   PubMed Web of Science ®Google Scholar
• Nal B, Altmeyer RM, Kien F, et al. Anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus. WO2008062309A2; 2008
   Google Scholar
• Altmeyer RM, Kien F, Jean M, et al. Anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus. CA2611106A1; 2008
   Google Scholar
• Millet JK, Kien F, Cheung CY, et al. Ezrin interacts with the SARS coronavirus Spike protein and restrains infection at the entry stage. PLoS One 2012;7:e49566
   Web of Science ®Google Scholar
• Dong S, Liu K, Ma J, et al. Long-acting thymosin alpha1-polyethylene glycol modifiers. CN101759805A; 2010
   Google Scholar
• Qie J, Ma J, Wang L, et al. Studies of bioactivity, conformation and pharmacokinetic profiles of site-specific PEGylated thymosin alpha 1 derivatives. Drug Metab Lett 2007;1:232-40
   PubMedGoogle Scholar
• Cho EH, Chung SG, Myung HN, et al. Urea derivatives, process for the preparation thereof, and antiviral composition containing the same. KR20080020862A; 2008
   Google Scholar
• Fukumoto S, Goto T, Hayashi S, et al. Anti-SARS coronavirus agent, and product containing anti-SARS coronavirus agent. TW201018473A; 2010
   Google Scholar
• Liang PH, Cheng WC, Lee YL, et al. Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis. ChemBioChem 2006;7:165-73
   PubMed Web of Science ®Google Scholar
• Liang PH, Lee YL, Wong CH. Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics. US2012046337A1; 2012
   Google Scholar
• Blatt LM. Compositions and methods for treating coronavirus infection and SARS. US2009068142A1; 2009
   Google Scholar
• Guilford JW, Faulds HD. Combination therapy treatment for viral infections. WO2011047048A1; 2011
   Google Scholar
• Jun X. Uses of selective JAK3 restrainer VI in antiviral mediated acute lung damnification. CN101401807A; 2009
   Google Scholar
• Park HJ, Park SJ, Kim YG. Homopiperazine-based compound suppressing ribosomal frame shift by binding to RNA pseudoknot structure of SARS coronavirus. JP2008156357A; 2008
   Google Scholar
• Park SJ, Kim YG, Park SJ. Identification of RNA pseudoknot-binding ligand that inhibits the -1 ribosomal frameshifting of SARS-coronavirus by structure-based virtual screening. J Am Chem Soc 2011;133:10094-100
   PubMed Web of Science ®Google Scholar
• Plant EP, Rakauskaite R, Taylor DR, et al. Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins. J Virol 2010;84:4330-40
   PubMed Web of Science ®Google Scholar
• Dinman JD, Wickner RB. Ribosomal frameshifting efficiency and gag/gag-pol ratio are critical for yeast M1 double-stranded RNA virus propagation. J Virol 1992;66:3669-76
   PubMed Web of Science ®Google Scholar
• Shum KT, Tanner JA. Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase. ChemBiochem 2008;9:3037-45
   PubMed Web of Science ®Google Scholar
• Jang KJ, Lee NR, Yeo WS, et al. Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem Biophys Res Commun 2008;366:738-44
   PubMed Web of Science ®Google Scholar
• te Velthuis AJ, van den Worm SH, Sims AC, et al. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010;6:e1001176
   PubMed Web of Science ®Google Scholar
• Lau SK, Li KS, Tsang AK, et al. Genetic characterization of betacoronavirus lineage C viruses in bats revealed marked sequence divergence in the spike protein of Pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications on the origin of the novel Middle East Respiratory Syndrome Coronavirus. J Virol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar